EventDr. Lior Nissim
Synthetic Gene Circuits for Cancer Immunotherapy
The future of biology and medicine lies at the intersection of engineering, materials science, chemistry, and nanotechnology. In particular, the fields of micro/nanoscale technologies have seen an unprecedented growth and development over the last decade. In this domain, I have been developing cutting-edge micro and nanoscale technologies to present precise solutions for real-world problems in biology and medicine, thereby improving human health and advancing public safety. Particularly, I develop innovative, user-friendly, ultra-sensitive, and specific diagnostic and therapeutic screening platforms in the fields of early cancer detection, infectious diseases, biomarker discovery, as well as forensics science. I also present innovative mobile health approaches on a daily-basis that would potentially report disease status of patients to physicians and nurses, accelerating the screening of individuals and minimizing health disparities at the remote settings. In this regard, I precisely manipulate biomolecules, cells, and viruses in small volumes, and integrate microscale tools with multifunctional nanotechnology modalities to record minute amount of biological signals at their native milieu. Furthermore, I aim to leverage these approaches for bed-side, where individuals can easily self-monitor their health status for personalized and precision medicine applications. All these examples from my research aim to push the limits of cell manipulations and engineering tools in order to provide real solutions to problems in the clinic.
About The Speaker
Dr. Nissim earned his PhD from Weizmann Institute in 2009. Later he did a postdoc at Weizmann Institute from until 2011. Afterwards he moved to MIT Synthetic Biology Center for his postdoctoral studies where he worked as research associate until 2018. Dr. Nissim research focus is synthetic biology enabled cancer immunotherapy. He is developing and designing synthetic genetic circuits to overcome difficulties in cancer immunotherapy. Currently, Dr. Nissim is an Assistant Professor at the Hebrew University of Jerusalem Medical School.